Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Insulin Lispro MM Intensive Therapy vs Standard Premixed Insulin in T2DM
NCT00393705Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2006
- Primary completion
- Mar 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 4, randomised, open-label trial of insulin lispro in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Hemoglobin A1c at 16 weeks. Started Oct 2006; status: completed.
02
Drugs
insulin lispro
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00393705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00393705.